p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer
Our preclinical findings indicate that p-AKT protein expression, rather than PTEN, may be a more reliable predictor of response to AKT inhibition combined with docetaxel. Using p-AKT as a parameter, we uncovered the efficacy of this combination in NE prostate cancer, highlighting the potential to refine patient selection criteria for future clinical trials.
Authors
- Natalie L. Lister (ORCID: https://orcid.org/0000-0001-9223-5875)
- Birunthi Niranjan (ORCID: https://orcid.org/0000-0002-9555-8378)
- Hipacia Werneck Gomes (ORCID: https://orcid.org/0000-0001-5243-8272)
- Michelle G. Richards
- Shivakumar Keerthikumar (ORCID: https://orcid.org/0000-0001-9865-9767)
- Andrew Ryan (ORCID: https://orcid.org/0000-0002-5337-4714)
- Renea A. Taylor (ORCID: https://orcid.org/0000-0003-2609-2380)
- Edmond M. Kwan (ORCID: https://orcid.org/0000-0002-7053-680X)
- Gail P. Risbridger (ORCID: https://orcid.org/0000-0003-3089-4028)
Institutions
- Discovery Institute (US)
- Peter MacCallum Cancer Centre (AU)
- Cabrini Hospital (AU)
- Eastern Health (AU)
- Monash Health (AU)
- TissuPath (AU)
- Monash University (AU)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3848
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Victorian Cancer Agency
- Monash University
- Tour de Cure
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- National Health and Medical Research Council
- Cancer Council Victoria